DeNovo Ventures
VC Fund
Saratoga, United States
DeNovo Ventures is a VC fund in Saratoga focused on Health Care and Biotechnology. DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would havesignificant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by investment success in selected medical device and biotechnology companies. With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. They invest in all stages of enterprise development and growth – from early stage to late stage. The unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.
- Total investments:
- 65
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries DeNovo Ventures invests in
Stages DeNovo Ventures invests in
Countries DeNovo Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 25 (38%)
- Biotechnology 17 (26%)
- Medical Device 17 (26%)
- Medical 11 (17%)
- Therapeutics 5 (8%)
Stage
- Series B 15 (23%)
- Series D 10 (15%)
- Series C 9 (14%)
- Funding Round 8 (12%)
- Series A 7 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Richard Ferrari
Co - Founder & Managing Director
|
Co - Founder & Managing Director | Total investments: 3 | Find email | |
David M. Mauney
co-founder and Managing Director
|
co-founder and Managing Director | Total investments: 10 | Find email | |
Frederick Dotzler
Managing Director
|
Managing Director | Total investments: 12 | Find email | |
Jay Watkins
Managing Director
|
Managing Director | Total investments: 13 | Find email | |
Joe Mandato
Managing Director
|
Managing Director | Total investments: 18 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Milo
|
Milo is a group action communicator, sophisticated wireless networking, audio processing & powerful hardware in a carefully crafted design. | $12M / Series A / Jan 08, 2023 | |
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $25M / Series F / May 02, 2018 | |
|
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $42M / Apr 27, 2017 | |
Spinal Kinetics
|
Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine.The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic andbiomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms. | $34M / Jun 04, 2014 | |
EndoGastric Solutions
|
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $30M / Series G / May 06, 2014 | |
TRIA Beauty
|
TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah,Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California. | $45.5M / Private Equity / Jul 09, 2013 | |
|
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $43M / Series D / Mar 05, 2013 | |
|
TRIA Beauty
|
TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah,Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California. | $7.5M / Oct 02, 2012 | |
|
EndoGastric Solutions
|
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $13M / Jun 21, 2012 | |
Astute Medical
|
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment.The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development. | $40.4M / Series C / Jun 07, 2012 | |
| See all 65 investments → | |||
Co-Investors
Delphi Ventures
12 deals together
Advanced Technology Ventures
7 deals together
Foundation Medical Partners
7 deals together
The Vertical Group
7 deals together
Johnson & Johnson Development Corporation
6 deals together
Latterell Venture Partners
6 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does DeNovo Ventures invest in?
DeNovo Ventures invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series D stage. Most of the 65 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact DeNovo Ventures?
Public channels for DeNovo Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DeNovo Ventures?
The team at DeNovo Ventures includes Richard Ferrari (Co - Founder & Managing Director), David M. Mauney (co-founder and Managing Director) and Frederick Dotzler (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
